Veracyte Secures Medicare Coverage for Genomic Thyroid Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Veracyte said today that Medicare contractor Palmetto GBA has agreed to cover its Afirma Gene Expression Classifier for use in thyroid nodule diagnosis.

The coverage decision means that Veracyte's genomic test "is now accessible to 40 million Medicare patients nationwide," the company said.

The Afirma test is intended to determine whether inconclusive thyroid nodule results are benign or suspicious for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.